Abstracts tagged "Autoantibody(ies)"

Abstract Number: 0701 • ACR Convergence 2025
Exploring Calcinosis On Hand X-Rays In Systemic Sclerosis: a Mayo Clinic Cohort
Maximiliano Diaz Menindez¹, Simran Ravindra Nimal², Michael Pham², Caroyln Harvey³, Leroy W. Griffing² and Vivek Nagaraja², ¹Mayo Clinic School of Graduate Medical Education, Phoenix, AZ, ²Mayo Clinic, Scottsdale, AZ, ³Mayo Clinic, Phoenix, AZ
Background/Purpose: Calcinosis is a vexing manifestation in patients with systemic sclerosis (SSc) with a variable prevalence among cohorts. Up to 86% of calcinosis cases are…
Abstract Number: 1322 • ACR Convergence 2025
High Rheumatoid Factor Titers and Biologic Persistence in RA: Beyond TNF Inhibitors
Sara Salas Santamaría¹, Marta Chao Moreira², Manuel Juárez³, Marta Novella-Navarro², Pilar Nozal², Ana Martínez², Carolina Tornero⁴, Cristina Bohorquez⁵, Ana Sánchez², Carmen Cámara², Eduardo López², Eugenio de Miguel² and Chamaida Plasencia-Rodríguez², ¹Hospital Universitario La Paz, Miranda de Ebro, Castilla y Leon, Spain, ²Hospital Universitario La Paz, Madrid, Spain, ³Rheumatology Unit, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain, ⁴Hospital La Paz, Madrid, Spain, ⁵La Paz University Hospital, Alcalá De Henares, Spain
Background/Purpose: Rheumatoid factor (RF), an autoantibody targeting the Fc portion of IgG, is one of the most studied biomarkers in rheumatoid arthritis (RA). High RF…
Abstract Number: 1726 • ACR Convergence 2025
Inflammatory arthritis immune related adverse events represent a unique autoimmune disease entity primarily driven by T cells, but likely not autoantibodies
Xingxing Zhu¹, yue Yu¹, Yangfen Li¹, Panwen wang², ying li², Chantal McCabe², shiju chen², Brenna Sharp², Amber Wolzen², Hannah Langenfeld¹, Andrew C. Hanson¹, Cynthia Crowson³, svetomir Markovic², John Davis¹, Haidong Dong², Uma Thanarajasingam¹ and Hu Zeng¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, ³Mayo Clinic, Stewartvillle, MN
Background/Purpose: The immunological basis of inflammatory arthritis (IA) immune related adverse event (irAE) following anti-PD-1/PD-L1 immune checkpoint inhibition (ICI) therapy is incompletely understood. The relationship…
Abstract Number: 2236 • ACR Convergence 2025
Treatment-induced autoantibodies in Rheumatoid Arthritis patients receiving anti-TNF inhibitors or JAK inhibitors
EVRIPIDIS KALTSONOUDIS¹, Nikolaos Kougkas², Panagiota Karagianni³, Tereza Memi⁴, Nikolaos Koletsos⁵ and Eleftherios Pelechas⁶, ¹Rheumatology Clinic, University of Ioannina, IOANNINA, Ioannina, Greece, ²⁴th Department of Internal Medicine, Aristotle University, Thessaloniki, Thessaloniki, Greece, ³BioAcuHealth.gr, Ioannina, Ioannina, Greece, ⁴University Hospital of Ioannina, Ioannina, Ioannina, Greece, ⁵School of Health Sciences, Faculty of Medicine, University of Ioannina, Department of Rheumatology, Ioannina, Greece, Ioannina, Ioannina, Greece, ⁶Hatzikosta General Hospital of Ioannina, Ioannina, Ioannina, Greece
Background/Purpose: Rheumatoid arthritis (RA) can coexist with other autoimmune disorders such as Sjögren’s syndrome and systemic lupus erythematosus (SLE). In these cases, the terms secondary…
Abstract Number: 2492 • ACR Convergence 2025
Autoantibody Profiles and Disease Trajectories in Early Systemic Sclerosis: Insights from a Prospective Cohort
Marzieh Jamali¹, Amisha Kaur¹, Suiyuan Huang¹, James St. Clair², John Varga¹, Carleigh Zahn², Erica Mulcaire-Jones¹, Alain Lescoat¹ and Dinesh Khanna¹, ¹University of Michigan, Ann arbor, MI, ²University of Michigan, Ann Arbor
Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disease with high mortality. Early stratification by autoantibody (SSc-Ab) profile may inform prognosis and management, but data…
Abstract Number: 0195 • ACR Convergence 2025
Utility of Repeat ANA Testing
Michael Luggen¹ and Sila Mateo Faxas², ¹University of Cincinnati College of Medicine, Cincinnati, OH, ²Good Samaritan Hospital, Cincinnati, OH
Background/Purpose: The ANA by immunofluorescence is a sensitive screening test for most systemic auto-immune rheumatic diseases (SARDs). A negative result is oftentimes sufficient to exclude…
Abstract Number: 0531 • ACR Convergence 2025
Evaluating the Diagnostic Utility of 14-3-3 eta Autoantibodies in Axial Spondyloarthritis: A Multiplex Assay Approach
Anthony Marotta¹, Walter P. Maksymowych², Stephen Bleakley¹, Stephanie Wichuk³ and Norma Biln⁴, ¹Augurex Life Sciences Corp, Vancouver, BC, Canada, ²Department of Medicine, University of Alberta, ⁵⁶⁸ Heritage Building, Edmonton, AB, Canada, ³University of Alberta, Edmonton, AB, Canada, ⁴Augurex Life Sciences, Vancouver, BC, Canada
Background/Purpose: Novel biomarkers for axSpA are urgently needed to enable earlier diagnosis and improve patient outcomes. An assay for quantifying 14-3-3η autoantibodies (AAbs) has been…
Abstract Number: 0711 • ACR Convergence 2025
Analytical Performance of a Novel, Fully Automated Multiplexed Microarray Immunoassay Prototype for the Simultaneous Detection of Autoantibodies to GBM, PR3, and MPO: A Multicenter Evaluation
Natalia Swierczynska¹, Ruaridh Armour¹, Anthony Yau¹, Enn Rusi¹, Mark Hooper¹, Jason Sillitoe², Caroline Wilson², Paula Griffiths³, Tariq El-Shanawany³, Faye Sims⁴, Gerber Gomez⁵, Christian Fischer⁵, Michael Hausmann⁶ and Helen Laird¹, ¹Research & Development, AliveDx, Edinburgh, Scotland, United Kingdom, ²North East Innovation Lab, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, England, United Kingdom, ³Immunology Department, Laboratory Medicine, Swansea Bay University Health Board, UK. Cardiff and Vale UHB, Swansea, Wales, United Kingdom, ⁴Clinical Biochemistry and Immunology Department Peterborough City Hospital, North West Anglia NHS Foundation Trust, Peterborough, England, United Kingdom, ⁵Scientific & Medical Affairs, AliveDx Suisse SA, Eysins, Switzerland, ⁶AliveDx Suisse SA, Eysins, Switzerland
Background/Purpose: Anti-neutrophil cytoplasmic antibodies (ANCA), including those directed to myeloperoxidase (MPO) and proteinase 3 (PR3) as well as antibodies against anti-glomerular basement membrane (anti-GBM) are…
Abstract Number: 1330 • ACR Convergence 2025
Sex and reproductive stage modify the role of endogenous estrogens on coronary atherosclerosis in rheumatoid arthritis and differences reflect effects on inflammation and cholesterol metabolism
George Karpouzas¹, Bianca Papotti², Sarah Ormseth³, Marcella Palumbo², Matthew Budoff¹ and Nicoletta Ronda², ¹Harbor-UCLA Medical Center, Torrance, CA, ²University of Parma, Parma, Italy, ³The Lundquist Institute for Biomedical Innovation, Torrance, CA
Background/Purpose: Endogenous estrogens associate with cardioprotective benefits in the general population. Yet, dual pro- and anti-inflammatory effects were described in autoimmune states depending on concentration,…
Abstract Number: 1814 • ACR Convergence 2025
Trapped in the NET: Impaired DNase function and targeted antibodies in the pathogenesis of pediatric lupus nephritis
Sohei Makita¹, Joyce Hui-Yuen², Bharati Matta³, Betsy Barnes⁴, Jenna Battaglia⁵, Tatiana Borja⁶, Boris Reizis⁷, Lydia Thomas⁸ and Kim Simpfendorfer⁹, ¹NYU, New York, ²North Shore LIJ Health System, Great Neck, NY, ³The Feinstein Institutes for Medical Research, Manhasset, NY, ⁴Northwell Health, Manhasset, NY, ⁵Northwell Health, Manhasset, ⁶Northwell Health- Cohen Children’s Medical Center, Elmhurst, NY, ⁷New York University Grossman School of Medicine, New York, NY, ⁸Northwell Health - Cohen Children's Medical Center, Lake Success, NY, ⁹Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: Up to 80% of patients with pediatric systemic lupus erythematosus (pSLE) can present with renal abnormalities. Treatment of pSLE is often difficult and includes…
Abstract Number: 2255 • ACR Convergence 2025
Diagnostic Accuracy of Anti-Carbamylated Protein Antibodies in Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Pannathorn Nakaphan¹, Patavee Pajareya², Priabprat Jansem³, Somkiat Phutinart², Nattanicha Chaisrimaneepan⁴ and Noppachai Siranart², ¹Department of Internal Medicine, Weiss Memorial Hospital, Chicago, IL, ²Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, ³Department of Psychiatry, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand, ⁴Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX
Background/Purpose: Anti-carbamylated protein antibodies (anti-CarP Ab) are emerging serologic markers in rheumatoid arthritis (RA). Anti-CarP Ab has a controversial diagnostic utility in RA but may…
Abstract Number: 2496 • ACR Convergence 2025
Comparing Long-term Outcome Across Systemic Sclerosis Subgroups Using a Multi-Organ Disease Progression Score
Philip Yee¹, medha kanitkar², stefano rodolfi³, Voon H. Ong² and Christopher Denton⁴, ¹Division of Medicine, Centre for Rheumatology, University College London, London, England, United Kingdom, ²Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, ³University College London, London, United Kingdom, ⁴University College London, UK, London, United Kingdom
Background/Purpose: Evaluating disease modification in systemic sclerosis (SSc) is challenging and requires long term studies. This is especially relevant to limited cutaneous (lc)SSc where severe…
Abstract Number: 0236 • ACR Convergence 2025
Safety and Efficacy of T Cell Engager Therapy in patients with refractory Autoimmune Disease
Laura Bucci¹, Sebastian Böltz¹, Melanie Hagen¹, Danae-Mona Nöthling¹, Tobias Rothe², Carlo Tur¹, Andreas Wirsching¹, Janina Auth³, jochen wacker¹, Markus Eckstein⁴, Stefano Alivernini⁵, Aline Bozec¹, Christina Bergmann¹, Maria Antonietta D'Agostino⁶, Maria Gabriella Raimondo¹, Georg Schett⁷ and Ricardo Grieshaber-Bouyer⁸, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ²Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlagen, Germany, ³Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ⁴Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander- Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ⁵Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁶Division of Rheumatology and Clinical Immunology - Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁷Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁸University Hospital Erlangen, Erlangen, Germany
Background/Purpose: T cell engagers (TCEs) are a promising therapeutic strategy to treat autoimmune diseases (AID). However, long-term data remain limited.Methods: Patients with treatment-refractory AID were…
Abstract Number: 0773 • ACR Convergence 2025
Clinical Significance of Anti-MDA5 Epitope Antibodies as Prognostic Indicators for Interstitial Lung Disease With or Without Dermatomyositis
Tsuneo Sasai¹, Ran Nakashima², Motohiro Nonaka³, Norimichi Nomura⁴, Atsubumi Ogawa¹, Yasuhiro Nohda¹, Mirei Shirakashi², Ryosuke Hiwa¹, Hideaki Tsuji¹, Hajime Yoshifuji², Shogo Matsuda⁵, Masao Katsushima⁶, Michinori Ishitoku⁷, Yusuke Yoshida⁷, Yasuyuki Todoroki⁸, Satoshi Kubo⁹, Tomohiro Handa¹⁰, Hiromi Tomioka¹¹, Ryo Tachikawa¹², Keisuke Tomii¹², Kiminobu Tanizawa¹³, Toru Arai¹⁴, Takuya Kotani¹⁵, Motomu Hashimoto¹⁶, Shintaro Hirata⁷, Yoshiya Tanaka¹⁷, Tsuneyo Mimori¹⁸ and Akio Morinobu¹⁹, ¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan, ³Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Department of Cell Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁵Department of Internal Medicine IV, Division of Rheumatology, Osaka Medical and Pharmaceutical University, Osaka, Japan, ⁶Department of Clinical Immunology, Osaka Metropolitan Graduate School of Medicine, Osaka, Japan, ⁷Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, ⁸Department of Molecular Targeted Therapies, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁹Department of Molecular Targeted Therapies (DMTT), University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ¹⁰Department of Advanced Medicine for Respiratory Failure and Graduate School of Medicine, Kyoto University, Kyoto, Japan, ¹¹Department of Respiratory Medicine, Kobe City Medical Center West Hospital, Kobe, Japan, ¹²Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan, ¹³Respiratory Medicine, National Hospital Organization Kyoto Medical Center, Kyoto, Japan, ¹⁴Clinical Research Center, NHO Kinki-Chuo Chest Medical Center, Sakai, Japan, ¹⁵Division of Rheumatology, Department of Internal Medicine IV, Osaka Medical and Pharmaceutical University, Osaka, Japan, ¹⁶Osaka Metropolitan University, Osaka, Japan, ¹⁷University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ¹⁸Takeda Clinic for Rheumatic Diseases, Kyoto, Japan, ¹⁹Kyoto University, Kyoto, Kyoto, Japan
Background/Purpose: Melanoma differentiation-associated gene 5 (MDA5) is a cytoplasmic RNA sensor and activates the innate immune response. Autoantibodies against MDA5 are associated with rapidly progressive…
Abstract Number: 0897 • ACR Convergence 2025
APECED Disease Reorganizes The B Cell Compartment Toward Alternatively Activated Subsets
william Galbavy, Hyunjin Kim, Brian Klotz, Marine Malbec, Carley Tasker, Eva Conde, Andrea Vecchione, Seblewongel Asrat, Benjamin Daniel, Weikeat Lim, Andre Limnander and Jamie Orengo, Regeneron, Tarrytown, NY
Background/Purpose: Autoimmune PolyEndocrinopathy Candidiasis Ectodermal Dystrophy (APECED) is a rare syndrome of multi-organ autoimmunity driven by the presence of self-reactive T cells and autoantibodies caused…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].